Printer Friendly

Waving a red flag against melanoma.

For years, a dilemma has stymied scientists' attempts to create a successful "vaccine" for treating cancerous tumors: In order to work, the vaccine would have to rally the patient's immune system into launching a more vigorous attack against cancer cells, but it would also have to leave normal cells unscathed.

Most cancer researchers agree that the key component of an anticancer vaccine would be an immune-stimulating protein, or antigen, that exists only on the surfaces of cancer cells. Now, European scientists report the discovery of such an antigen on tumor cells taken from people with malignant melanoma.

In a complex series of laboratory experiments, the team identified a protein that serves as a red flag to incite the killer instincts of the melanoma patient's own cancer-fighting cells. They also identified the gene that codes for the protein's production.

"This is the first time that a [cancer-cell] antigen recognized by [immune-system cells] has been identified," asserts Thierry Boon, of the Ludwig Institute for Cancer Research in Brussels. Boon, who directed the new study, speculates that injections of human cells bearing this protein might help fend off the disease in up to 10 percent of all Caucasian melanoma patients.

Malignant melanoma, which affects the skin's pigmented cells, will strike an estimated 32,000 people in the United States this year. Most melanoma victims are Caucasian. In the earliest stage of the disease, patients develop one or more irregularly shaped, varicolored spots that grow progressively larger.

Melanoma is the deadliest form of skin cancer, killing one-fifth of its victims within five years despite surgical removal of the lesions, chemotherapy and radiation treatment. Oncologists estimate that only 30 to 40 percent of all melanoma patients derive any benefit from standard chemotherapy, and most of those eventually suffer fatal recurrences.

This dire prognosis has spurred attempts by researchers worldwide to create a vaccine for melanoma patients. Last year, a California group eliminated skin tumors in all 25 participating melanoma patients by injecting the lesions with monoclonal antibodies against a particular fatty molecule sometimes present on the surfaces of cancer cells, although most of these patients later died from other melanoma tumors (SN: 5/26/90, p.324). Other research teams have shrunk melanoma tumors by inoculating them with killed melanoma cells, which apparently bolster the body's immune response (SN: 3/30/91, p.207).

Boon and his colleagues predict that their newly discovered protein will trigger a more specific antitumor response, potentially lengthening patients' lives. "The idea [to develop a melanoma vaccine] is certainly not new," Boon concedes. "But what is new is that we may now be able to vaccinate with a given antigen a person who we know carries this antigen on his tumor," thereby stimulating the immune system more effectively.

In the Dec. 13 Science, his group reports finding the antigen on some tumor cells taken from melanoma patients. They discovered the distinctive protein wedged into the cells' major histocompatibility complexes (MHC) - clumps of outer-membrane proteins that body cells use to tell each other from foreign cells.

In laboratory tests, the researchers found that the immune-system cells of patients with a particular type of MHC, known as HLA-A1, could detect tumor cells bearing the novel protein, recognize these cells as foreign, and kill them. The immune-system cells, called T-cells, ignored normal cells carrying HLA-A1 but lacking the tumor antigen.

HLA-A1 occurs in 25 percent of Caucasians but is less common in blacks and Asians.

Boon's group now plans to give immune-system cells to melanoma patients with HLA-A1 whose tumors make the newly discovered protein. However, he cautions, "we have no proof that this is going to work" to bolster the patients' rejection of their tumors.

Steven A. Rosenberg of the National Cancer Institute in Bethesda, Md., praises the new discovery. "This is an excellent piece of work," he says. "I'm thrilled."

Rosenberg and his colleagues are testing several gene-therapy treatments for melanoma, including one using tumor cells engineered with genes that code for two naturally occurring anticancer substances. Last May, he announced that his group was close to finding the gene for a melanoma tumor antigen (SN: 5/25/91, p.326). But he concedes that the European scientists got there first.
COPYRIGHT 1991 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Author:Ezzell, Carol
Publication:Science News
Date:Dec 14, 1991
Words:700
Previous Article:Beware of Greeks bearing culture.
Next Article:Software failure: counting up the risks.
Topics:


Related Articles
Taking a shot at melanoma.
Melanoma: can the sun be protective?
Melanoma shrinks from human monoclonals.
Sunscreen can't give blanket protection.
Birch bark has an anticancer bite.
Psoriasis balm boosts melanoma risk.
Skin Check.
Sun struck: data suggest skin cancer epidemic looms.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters